All News

Help patients choose appropriate medications and direct them to a physician, when necessary

Although marginal zone lymphoma is relatively rare, it contains a broad spectrum of conditions under it that require an individualized treatment selection process.

Multiple myeloma has remarkable genetic heterogeneity, which can make it challenging to identify proper prognostication and clinical management for patients.

Ten quiz questions to assess your knowledge on common symptoms and treatments for ectopic pregnancy.

Mononucleosis isn't as contagious as some infections, such as the common cold.

Investigators in a clinical study evaluating the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in children aged 6 months to under 5 years noted that their research will continue with new changes.

Abatacept is also approved for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, and moderate to severe polyarticular juvenile idiopathic arthritis for children 2 years of age and older.

The treatment was first approved in 2013 for adults as a 1500 mg course of treatment, administered as 2 doses of 750 mg each separated by at least 7 days.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses minimum residual disease-driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax in previously untreated chronic lymphocytic leukemia.

Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity, addresses disparities occurring in diabetes care among racial and ethnic populations.

Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health (ORWH) at the National Institutes of Health (NIH), discusses the scope and focus of the work of NIH ORWH.

A panel of experts discuss the future of psychedelic medicine and the role of the pharmacy in that future.

The new analysis includes approximately 1100 women without type 1 or type 2 diabetes (T2D) who subsequently gave birth at least once during the 25-year study period, which ended in 2011.

Cutaquig was recently approved for the treatment of pediatric patients aged 2 years and older with primary humoral immunodeficiency.

Study may help guide COVID-19 vaccination strategies for patients with blood disorders.

Researchers to explore possible approaches for designing small molecule therapeutics to combat depression.

Fetal alcohol syndrome causes brain damage and growth problems.

Study shows moderately reduced efficacy of the Moderna COVID-19 vaccine over time against Delta infection, which supports current booster dose recommendations.

Major metabolites for cannabinoids may interfere with two families of enzymes that help metabolize a wide range of drugs prescribed for a variety of conditions.

Health service planning involves a myriad of stakeholders to ensure their sustainability and their integration into other aspects of community health.

Trial seeks to provide high-level evidence for improving the initial treatment for acute Kawasaki disease.

A single booster dose of the GlaxoSmithKline and Sanofi recombinant adjuvanted COVID-19 vaccine candidate delivered consistent and strong immune responses.

Up to 60% of arteriovenous fistulas fail to develop properly due to smooth muscle cell hyperplasia.

Neosporin prevents/treats only bacterial skin infections.

Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors.

The "Melt the Phones" campaign is just one of the most recent ways that independent pharmacies and other organizations are working toward DIR reform.

After the initial infection, herpes virus lies dormant in the body and can reactivate several times a year.

The safety profile observed in patients with active psoriatic arthritis administered upadacitinib was consistent with the safety profile observed in patients with rheumatoid arthritis.

The unique challenges that pharmacy learners encountered during the COVID-19 pandemic reinforce their importance in the professional pharmacy setting.

This trial is the first to assess the use of isatuximab as a first-line treatment for newly diagnosed, transplant-eligible patients up to 70 years of age, according to the study authors.